Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

CytoVeris Appoints Scott Flora, Medical Device Executive, as Strategic Advisor


News Image

CytoVeris Inc., an emerging company formed with the vision to change the paradigm in cancer surgery through the introduction of optical-based “guided surgical tools,” today announced the appointment of Mr. Scott Flora to its Advisory team. Currently Board Chair for Palliare Ltd, Conventus Orthopaedics and New View Surgical, Mr. Flora brings to CytoVeris significant knowledge and more than 40 years of medical device experience in implantable devices and surgical instruments.

“We are excited to have Scott join us as a strategic advisor,” said Dr. Alan Kersey, President and CEO of CytoVeris. “We are eager to leverage his extensive industry experience and surgical device domain expertise to pursue our mission of disrupting the current paradigm of breast cancer surgery and improve the lives of cancer patients,”

Mr. Flora has previously held several leadership roles including Interim President and CEO of Invuity, Executive Director of Conventus Orthopaedics, President and CEO of OmniGuide Surgical, President of Covidien’s Surgical Device Group and President of Smith & Nephew Orthopedic Reconstruction. He has also served on three public company boards including Invuity, MAKO Surgical and Tengion.

“Our advisors provide invaluable guidance and direction as we pursue our mission at CytoVeris,” commented Mr. Patrick Curry, Chief Operating Officer and Vice President of Finance of CytoVeris. “We are thrilled to welcome Mr. Flora, an accomplished business professional, to this esteemed group and look forward to his guidance.”

About CytoVeris:

Through the introduction of optical “guided surgical tools” that allow for the real-time detection of cancer in an intraoperative setting, CytoVeris is on a mission to change the current paradigm in cancer surgery – ensuring surgeons can remove all cancer in a single surgical procedure. CytoVeris is leveraging the convergence of powerful optical technologies, knowledge of biochemical alteration during carcinogenesis, and explainable artificial intelligence to bring new capabilities into the hands of surgeons, and drive improvements in patient outcomes. We are driven by a passion for science and compassion for cancer patients. For more information, please visit: https://www.cytoveris.com

Share article on social media or email:

Avalon Dental Group in Sugar Land, Texas, has been Recognized by Find Local Doctors as a 2020 Top Patient Rated Sugar Land Dentist


News Image

We are honored to be recognized as a 2020 Top Patient Rated Dentist. I am so proud of the long-term relationships we have established with our valued patients. says, Dr. Dannie Yu

Avalon Dental Group recently moved to its new state-of-the-art clinic and is now located at 2225 Williams Trace Blvd, Suite 111 in Sugar Land, TX. Find Local Doctors has awarded this practice the title of being a 2020 Top Patient Rated Sugar Land Dentist. Avalon Dental Group has received a large number of five-star ratings and superior reviews from real patients. Find Local Doctors is a trusted online directory that helps consumers easily locate top-notch, reputable physicians and dentists in their area. This well-respected practice is among an exclusive group to receive a high volume of outstanding reviews.

Avalon Dental Group welcomes patients of all ages, providing excellence in dentistry for the entire family. Practice founder Dr. Dannie Yu, Dr. Shinoy Abraham and the rest of the team of dental professionals are well-known for the comprehensive patient care they provide at Avalon Dental Group. Services they offer include general dentistry, cosmetic dentistry, pediatric dentistry, restorative dentistry, sedation dentistry and orthodontics. The skilled dental team is committed to providing high-quality treatments, offering a wide menu of services ranging from routine cleanings and beautiful, natural-looking smile makeovers to restorative dentistry. Avalon Dental Group provides the latest in advanced technology and modern amenities to ensure patient comfort. The friendly staff members, convenient scheduling options, insurance and financing assistance and will assure you a stress-free experience from your very first visit. Dr. Yu and the rest of the team are passionate about helping patients meet their dental goals. Many of the exceptional patient reviews commented on the world-class treatment and personalized attention they receive when visiting the practice.

“We are honored to be recognized as a 2020 Top Patient Rated Dentist. I am so proud of the long-term relationships we have established with our valued patients,” says Dr. Dannie Yu

More about Dr. Dannie Yu:

Dannie S. Yu MS, DDS, earned his dental degree from the University of Michigan. Dr. Yu is credentialed by the International Congress of Oral Implantologists (ICOI). A published biochemistry researcher, Dr. Yu brings many years of scientific training and expertise with his unique artistic background to the benefit of Avalon Dental Group’s patient family. Relying on his faith and professional ethics, he decided to bring his vision of a dental practice that provides the most advanced and proven dental care as a respected neighborhood dentist. Over the years, Dr. Yu and Avalon Dental Group have provided compassionate care to thousands of loyal neighbors and friends that comprise their patient family.

For more information on the services offered at Avalon Dental Group or to schedule an appointment, please visit http://www.theSugarLanddentist.com or call (281)-2014-8496.

Share article on social media or email:

Shango Wins Top Prize in G.O.A.T. Cup Contest


Shango Wins Top Prize in G.O.A.T. Cup Contest

“I can honestly say without being biased that Shango was definitely the best in the top category,” said Alex Hoggan, Director of Business Operations for Chemhistory, the title sponsor of the contest.

Shango cannabis won the highest honor in the top growers category at the inaugural G.O.A.T. Cup cannabis contest. Shango Oregon’s exclusive strain, Alien Banana Candy, took first place in the High Range THC category (28% and above) in the Indoor and Mixed Light division.

Entries were judged on three levels: Seventy percent of the score was determined by the highest THC over three testing runs, 20% was based on presentation, taste and aroma, and 10% was based on consumer votes.

Shango Alien Banana Candy tested at a whopping 35.45% THC level. The next closest finisher tested at 31%.

“I can honestly say without being biased that Shango was definitely the best in the top category,” said Alex Hoggan, Director of Business Operations for Chemhistory, the title sponsor of the contest.

Chemhistory is one of the top three testing laboratories in Oregon in terms of volume.

“Shango is one of the top-tier growers in the state,” Hoggan added. “The state THC average in our lab testing is 18% and all Shango strains always test above 20%.”

But Shango’s Master Grower, Shane McKee, insists that the winning THC level was no fluke and that higher test counts can be expected in the future.

“It doesn’t stop at 35%,” McKee said.

Alien Banana Candy is a top-shelf attraction at Shango’s Portland dispensary, as well as at numerous Shango retail partners throughout Oregon.

“Our lead grower at Shango Oregon is Mikal Osborne and he did exactly what he was supposed to do,” McKee continued. “With key guidance over the years, this strain has become a fine example of his handiwork. We can’t keep it on the shelf. It flies out the door.”

McKee was also pleased with the winning strain’s terpene content that tested at 3.05%. “We’ve had some product that’s almost 5%, but everything north of 3% is noteworthy,” McKee said.

“Shango spends a lot of time and money breeding, hunting and acquiring cultivars, but most guys just get a clone from somebody and they’re only focused on making money in production,” McKee said. “Sometimes it literally takes years of hunting and testing before we move a cultivar into production. We do extensive testing of phenotypes multiple times to make sure we’ve chosen the right phenotype of each cultivar.”

The process begins with the all-important selection of seeds, McKee says. “We’ll try to go through 100 or more seeds to find that perfect cultivar.

“We pay attention to every detail from mother plant to packaging to ensure we’re always putting out the best flower possible,” McKee added. “One person can grow a strain and get 18% THC while another person can grow the same strain and get 26%. Attention to detail can be the difference between poor and amazing THC, terpenes and customer satisfaction.”

The G.O.A.T Cup is a cannabis growers competition created and designed to highlight and promote the best growers in Oregon’s cannabis industry. The contest is based in science and works with Chemhistory, an ORELAP accredited laboratory, to perform the testing.

“I like the G.O.A.T. Cup approach of being judged on statistical analysis combined with customer satisfaction,” McKee said.

This event will be held every two years.

“It will grow even larger over time,” Hoggan said. A video of the awards ceremony is available on Instagram.

According to The G.O.A.T. Cup organizers, all entries were triple-blind tested by an accredited laboratory, with the following score weighting:

  • 70% of score: Total cannabinoids (10 cannabinoids) and terpenes (52 terpenes) averaged for a final score
  • 20% of score: Presentation, trichomes, trim and aroma
  • 10% of score: Consumer vote

Other THC categories for the contest included Mid High Range (21 to 27.9% Indoor), Mid-Range (15 to 20.9% Indoor) and Mid-Range (15 to 20.9% Greenhouse).

Shango will be featured in the Oregon Leaf and the Daily Leaf, as well as on the G.O.A.T. Cup Trophy. Shango will also be able to use the licensed G.O.A.T. logo on products and digital and/or published marketing materials for two years.

Alien Banana Candy is available at Shango Harold, located at 8056 SE Harold St. near 82nd and Foster in Portland, as well as at select Oregon dispensaries listed on http://www.goshango.com.

Entries for The G.O.A.T. Cup received Full Compliance Testing for potency, pesticides, water activity and moisture. Potency was tested in triplicate and terpenes levels were tested in duplicate.

Chemhistory is a dedicated QA/QC laboratory providing analytical screening services for farmers, product producers, distributors and consumers.

“Our laboratory meets and exceeds all requirements through analytical testing methodologies, state-of-the-art instrumentation, and highly trained scientific personnel,” Hoggan said.

“This makes the G.O.A.T Cup a level playing field for all entries,” Hoggan said.

                                                                         #

About Shango

Shango is an established vertically integrated cannabis brand offering a full range of award-winning products, including flower, extracts and cannabis-infused edibles, in Oregon, Michigan and Nevada. The Shango brand has multiple full-service recreational and medical cannabis dispensaries in Oregon and Nevada, as well as a medical cannabis provisioning center in Michigan.

Shango will open a second provisioning center in Bay City, Michigan, on Nov. 19. A state-of-the-art cannabis distribution operation in Southern California will be opening soon and the company is also set to open the first of three Missouri dispensaries in 2021. In Q2 2020, Shango’s Michigan operations will add a third provisioning center located in Hazel Park, as well as two extraction facilities, a commercial kitchen and an indoor cultivation facility.

A recognized leader in the cannabis industry, Shango sets the standards for product quality, consistency and business conduct. Shango is committed to cannabis education and is a fierce advocate of the safe and responsible use of cannabis products. For more information, go to http://www.goshango.com.

ExsoMed Corporation Announces Completion of MDSAP Certification and ISO 13485:2016 Audit with Zero Findings


ExsoMed Corporation, a privately held U.S.-based medical device company providing orthopaedic surgeons with innovative solutions in hand surgery, announced that it has successfully completed Medical Device Single Audit Program (MDSAP) certification and ISO 13485:2016 audits, with no open findings.

MDSAP is a program that allows for one regulatory audit of a medical device manufacturer’s quality management system (QMS) that satisfies the requirements of multiple regulatory jurisdictions. Audits are conducted by Auditing Organizations authorized by the participating Regulatory Authorities to audit under MDSAP requirements. Certification allows medical device manufacturers to be audited once for compliance with regulatory requirements for four additional medical device markets outside of the United States: Australia, Brazil, Canada, and Japan.

“MDSAP certification validates ExsoMed’s ongoing commitment to maintaining the highest quality assurance standards within the medical device industry as required by regulatory bodies across the world,” said Daniel Mickelsen, ExsoMed’s Chief Operating Officer. “We are very proud of our team for this significant accomplishment.”

“With ExsoMed’s products experiencing tremendous success in the United States, many hand surgeons and distributors from the international marketplace have also requested our innovative offerings,” shared James Young Kim, ExsoMed’s Managing Director of Global Sales and Marketing. “MDSAP certification now allows us to enter some of the most important healthcare markets in the world and raise the standard of care in hand surgery for their patients, surgeons, and facilities. We are looking forward to sharing more international updates in the coming months.”

About ExsoMed

ExsoMed is a privately held medical device company providing orthopaedic surgeons with innovative solutions in hand surgery. We believe that our solutions raise the standard of care in hand surgery by providing state of the art surgical tools that streamline use in the operating room, reduce the global cost of care, and enhance outcomes so that patients can get back to life faster. For more information regarding ExsoMed, please visit http://www.exsomed.com.

Share article on social media or email:

Echelon Fitness Launches Fully-Licensed Music Offering for Fitness Classes via MediaNet’s Enterprise Platform


By transitioning its music functionalities to MediaNet’s Enterprise platform, Echelon is unlocking the potential for expanded music content implementations and gaining world-class rights management capabilities.

Echelon Fitness, the company redefining home fitness, has launched a fully-licensed music offering with MediaNet, the world’s most advanced music distribution and rights management platform. MediaNet will provide Echelon a single point of service for music catalog and rights management using the expansive MediaNet Enterprise platform.

Echelon has experienced tremendous growth since 2019, expanding nearly 600% through their combination of cutting-edge technology, approachable fitness routines, and wide-ranging home fitness products.

Echelon Fitness’ suite of connected fitness products, including a rower, indoor bikes, touch-screen fitness mirrors, and commercial products, are revolutionizing the way people get fit. Music is a key driver of user motivation and workout efficiency, and Echelon’s relationship with MediaNet unlocks fully-licensed tracks from the top labels and publishers to propel users during a workout.

“MediaNet is passionate about the fitness space, and Echelon is a market leader in connected fitness experiences,” said MediaNet Vice President of Operations, Jeff Wallace. “By transitioning its music functionalities to MediaNet’s Enterprise platform, Echelon is unlocking the potential for expanded music content implementations and gaining world-class rights management capabilities. We expect this relationship to be great for Echelon users and great for the musicians, songwriters, and performers who provide the music on their platform.”

MediaNet, the only digital music platform that provides music content and rights management under one roof, will provide licensing, catalog, and rights management services for Echelon through its powerfully customizable MediaNet Enterprise product integration, which allows music applications to access a rich catalog of over 85 million new and classic tracks of all genres.

Through MediaNet’s Enterprise platform, Echelon Fitness can provide a richer user experience around music, exercise enhanced licensing control, and leverage the best core metadata in the music business for accurate, timely royalty payments.

“Music is such a massive part of our member experience and having the ability to quickly and easily curate custom playlists for our over 1200 live classes per week is critical to our success story,” said Echelon CTO, John Santo. “That’s why we decided to work with with MediaNet. Among other things, MediaNet’s single point of service and intelligent identification tools keep us moving in the right direction – and with confidence.”

To learn more about Echelon Fitness or to purchase one of their industry-leading connected fitness products, visit http://www.echelonfit.com.

About MediaNet

MediaNet is an advanced music distribution and rights management platform designed exclusively for business. For two decades MediaNet has offered companies of all sizes powerful technologies for music data, catalog, licensing, and royalties. MediaNet is the only digital music platform that provides single-point service through MediaNet’s worldwide sound recording catalog and comprehensive database of ownership and rights, for a truly rights-managed experience. MediaNet was acquired by SOCAN in May 2016. For more information, please visit: http://www.mndigital.com.

About Echelon

Echelon Fitness has been revolutionizing at-home connected fitness since deputing its first Connect Bike in 2017. What began as a mission to make healthy living attainable and accessible to all evolved into a line of innovative fitness solutions—as well as a thriving community. Ranging from sophisticated indoor cycling bikes, to touch-screen fitness mirrors and more, every product boasts thoughtful design and state-of-the-art technology, enabling people to exercise how they want, when they want and with who they want. By leveraging The Echelon Fit App and United Membership, members gain access to a variety of live and on-demand classes led by down-to-earth fitness instructors. Members can also use the app to track their performance against Echelon’s live leaderboard and overall progress, all while enjoying some healthy competition. For more information, visit https://echelonfit.com/.

Share article on social media or email:

Complimentary Webinar Offers Consumer Tips For Filing Mental Health Parity Insurance Appeals


“A primary goal of The Health Insurance Appeals Guide and this webinar is to empower individuals to better understand their rights to file a health insurance appeal”, notes Mary Covington, President, Denials Management and co-author.

Several leading health insurance experts will be providing guidance on how to navigate the health insurance appeals process after a denial of care during a complimentary webinar scheduled for December 10, 2020 at 2:00 p.m. ET. To register for the webinar click here.

The webinar builds upon The Health Insurance Appeals Guide which was published by Denials Management to inform consumers and treating providers on the key steps when filing appeals claims associated with mental health and substance use disorder (MH/SUD) treatment services. Complimentary copies of the Guide can be downloaded here.    

Over the last several decades, many federal and state laws have been adopted to protect consumers and providers when a health insurer denies a request for coverage or does not reimburse for care. Unfortunately, hundreds of different pathways exist when filing an appeal depending on what type of health insurance coverage is involved, where the patient lives, the type of adverse benefit determination, the timing of the denial, and the level of appeal.

Given all of this complexity, the webinar will highlight many of the key touchpoints to successfully file a health insurance appeal. The session will feature tips from experts who have decades of experience helping consumers and providers reverse insurance denials.    

The December 10th webinar will be moderated by Garry Carneal, JD, MA, President & CEO, Schooner Strategies, and will feature two nationally-recognized speakers:

-Mary Covington, President, Denials Management

-Brian S. King, JD, Founder, Brian S. King, PC.

“A primary goal of The Health Insurance Appeals Guide and this webinar is to empower individuals to better understand their rights to file a health insurance appeal”, notes Mary Covington, President, Denials Management and co-author. “Whether the individual is a patient, provider, family member, caregiver, or advocate, our shared health care goal is to get the right care to the right patient at the right time. Unfortunately, this is easier said than done.” Ms. Covington and her advocacy firm have helped hundreds of patients and providers reverse denials to ensure patients are getting the care they need.

“After the appeals process is exhausted, patients and providers often only have one choice and that is to sue the health plan, third party administrator or self-funded employer plan sponsor to ensure inappropriate denials are not upheld,” remarks Brian S King, Founder, Brian S. King, PC. “Over the years, the courts have begun to recognize the need to allow plaintiffs to have their day in court to protect against unlawful parity violations.” Mr. King is a national expert in this type of litigation, including challenging health plans regarding mental health parity violations pursuant to The Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 also known as MHPAEA.

The webinar and publication are sponsored in part by Schooner Strategies to help promote transparency and equity regarding how MH/SUD services are covered and reimbursed by health plans.

About Denials Management, Inc. –http://www.fixmyclaim.com

Facing medical, behavioral health, or substance abuse issues can be emotionally challenging and financially stressful for families. Similarly, the Denials Management advocacy team understands that providers must focus on the treatment of their patients rather than navigating through complicated utilization review, claims, and appeal processes. Since 1990, Denials Management has been partnering with families and providers to assist in resolving the specific insurance problems they are facing. Our experienced medical insurance advocates offer a variety of services, such as claims management, fighting insurance denials, and much more.

About Brian S. King, PC – http://www.erisa-claims.com

Brian S. King has established a reputation of protecting and upholding the rights of consumers and health care providers dealing with denied medical, disability and life insurance claims. The firm specializes in helping individuals navigate through the confusing and frequently hostile insurance claims process and also assists medical providers to appeal and litigate wrongful medical claim denials. The law firm’s advocacy work helps stem the tide of bad faith insurance practices, which are now more endemic than ever before. Brian S. King, PC helps their clients get the benefits and compensation promised to them.

About Schooner Strategies – http://www.schoonerstrategies.com

Schooner Strategies is a leading force in healthcare policy development, accreditation programs, government relations support, operational management, and business development, benefiting dozens of clients since 2007. Schooner arms clients with the tools, resources and industry knowledge to optimize their business mission and goals. Schooner provides the ideas, strategies and tactics to conduct original research, gather vital industry-specific data and acquire important market intelligence and trends information. Schooner also can help clients manage and staff their organizations. The consulting firm is located in downtown historic Annapolis, Maryland.

Share article on social media or email:

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO™ (pralsetinib)


The expertise that our scientists in Nottingham brought to the development program supported Blueprint Medicines’ efforts to rapidly gain regulatory approval, and through expedient tech transfer within our company’s global network, our team in Kansas City can effectively support commercial supply

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

This agreement will continue Catalent’s involvement in the GAVRETO program, which has been supported by Catalent’s Nottingham, U.K., site since 2015.

GAVRETO is a once-daily oral RET-targeted therapy that is designed to selectively and potently inhibit RET alterations that drive many cancer types, including approximately one to two percent of patients with metastatic NSCLC. Currently, RET is one of seven NSCLC biomarkers that can be targeted with an FDA-approved therapy.

“We have a long-standing relationship with Blueprint Medicines, and this approval marks an amazing accomplishment, reflecting the hard work, dedication and determination of the entire team,” commented Jonathan Arnold, President of Oral and Specialty Delivery at Catalent. “The expertise that our scientists in Nottingham brought to the development program supported Blueprint Medicines’ efforts to rapidly gain regulatory approval, and through expedient tech transfer within our company’s global network, our team in Kansas City can effectively support commercial supply.”

In February 2020, Catalent announced a commercial supply agreement for Blueprint Medicines’ AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

Catalent’s Kansas City, Missouri site is home to the company’s Oral & Specialty Drug Delivery business, where it provides a range of integrated services for oral solid dosage forms, from formulation development and analytical testing to clinical and commercial-scale manufacture. The 421,665-square-foot facility is the commercial manufacturing Center-of-Excellence for accelerated development programs and roller compaction. It also houses large-molecule analytical services and provides clinical supply services.

Blueprint Medicines, AYVAKIT and GAVRETO are trademarks of Blueprint Medicines Corporation.

Please click here to see the full Prescribing Information for GAVRETO.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

MedShift Connect Completes Digital Influencer Campaign for Lumiton


MedShift Connect announced today the conclusion of its Wear Healthy campaign, a digital influencer campaign for its client, Lumiton. While the campaign’s main drive was to increase mask sales, it was also designed to boost sales for all Lumiton apparel.

MedShift Connect is the in-house communications and marketing agency of MedShift, a medical technology company based in Charlotte, North Carolina. Lumiton is a technology company that works to transform textiles into a light delivery system for enhanced performance, protection, comfort and wellness. The agency has been working with Lumiton since September 2020, and has plans to continue working with the brand in the future.

The influencer campaign, which ran throughout the month of October, featured Charlotte businesswoman and beauty guru, Lindsey Regan Thorne.

“Lumiton was one of the best collaborations and companies to partner with. I believe in their science, their method, and I’ve worn their fabrics to know and trust the brand, but working one-on-one with them was absolutely seamless,” said Lindsey Regan Thorne.

Through implementation of the digital influencer campaign and a consistent and engaging posting strategy, the Lumiton Instagram account reached over 28,000 unique accounts since the beginning of the partnership.

“Our team has worked diligently to boost Lumiton’s brand awareness and to accelerate sales of all products since the beginning of our partnership. We feel that the digital influencer campaign played a huge role in increasing Lumiton mask sales, and we expect sales to continue to increase in the coming months” said MedShift’s Vice President of Communications and Marketing, Victoria Olszowy.

In addition to the digital influencer campaign, MedShift Connect managed the Lumiton internal social channels for brand enhancement purposes. The agency manages the textile innovator’s digital content creation, copywriting, and hashtag optimization, and will continue to do so for the foreseeable future. So far, the Lumiton Instagram account has experienced a 47% growth in follower count under the management of MedShift Connect, and the numbers are expected to continue rising throughout the remainder of the 2020 year. Additionally, since the beginning of the partnership, the Lumiton Instagram account has experienced a 20% engagement rate increase.

“I am incredibly grateful to the talented marketing team at MedShift Connect. Faced with a limited budget and competing election-year content, the digital influencer campaign they developed for our Lumiton mask increased sales 1,000% and generated over 60,000 views. A fantastic result! We look forward to developing a long-term relationship for future projects,” said Gates Hinds, co-founder of Lumiton.

For more information on Lumiton and the digital influencer campaign, visit the Lumiton website today.

About MedShift

MedShift, founded in 2015 in Charlotte, NC delivers a platform as a service to both medical device manufacturers as well as individual medical practices. Foundationally, MedShift enables access to the latest devices and technology to remain competitive and attract new business. MedShift has partnered with over 330 doctors in North America, Australia, and New Zealand to give practices the latest in cutting-edge treatment modalities, services, and systems.

MedShift is disrupting the traditional aesthetic device market by offering permanent placement, holistic subscription services for surgeons, physicians, and their business. MedShift’s broad portfolio of services for practices includes a portfolio of 25 leading aesthetic medical devices from nine manufacturers, an aesthetic eCommerce and subscription platform, in-house communications and marketing services, and inbound lead generation. For manufacturers, MedShift delivers a highly secure IoT platform consisting of both hardware and software assets allowing for real-time visibility, remote management, and big data modeling of entire medical device lineups. MedShift adds value across the manufacturer and provider spectrum and continues to empower robust integration with the leading brands and doctors in the industry. Additionally, in its first year of eligibility, MedShift ranked 185 on the 2020 Inc. 5000 list, leading as the 15th fastest growing health company in the United States.

Share article on social media or email:

Clinical Research Process is Explained in December 8th Webinar


“This unique online program will answer a lot of key questions about the clinical research process, how clinical trials work, and what to expect as a study participant´ said Joan Chambers, Senior Director at CISCRP.

The AWARE for All – Miami webinar is an important program that builds awareness about both clinical research participation and the critical role that individuals who participate in clinical trials play in advancing new medicines and treatments.

The Center for Information and Study on Clinical Research Participation (CISCRP) invites the Miami community to attend AWARE for All, a free webinar about clinical trials on Tuesday, December 8th, from 4-6pm EDT via a customized, secure online platform.

For the vast majority of individuals, the idea of clinical trials is a new and unfamiliar one. Most people first learn about clinical trials at the same time they are diagnosed with a serious illness for which no medication is available or adequate. Patients, their families, friends and health care providers must gather information quickly to make decisions about whether to participate. This rush to navigate the unfamiliar terrain of clinical trials is often overwhelming and confusing.

CISCRP’s AWARE for All – Miami program comes at a critically important time. Public interest in learning about clinical trials is high and the need for study volunteers in all disease conditions—including COVID-19 clinical trials—has increased significantly. The free program aims to offer an introduction and insight into the clinical research process, the decision to participate, and even the research team and their roles. Led by CISCRP, a non-profit, and supported by local research organizations, advocacy groups and a consortium of biopharmaceutical and service provider companies, the educational program is open to all members of the public.

Clinical research participant Jim Butler thanks his wife who brought the clinical trial opportunity to his attention and feels it was “an important way to be proactive about his diagnosis.” Jim referred to his research participation as something that he “feels really good about doing and is glad he can contribute to…”

Tomma Hargraves is a clinical trial participant and credits her participation with surviving Stage 3 lung cancer 14 years ago. Since then, she has participated in other clinical trials and serves as a patient liaison helping others navigate clinical trials.

Dr. Rishi Kakar, Chief Scientific Officer & Associate Medical Director, Segal Trials will be the overview speaker. In addition to a facilitated conversation with patients, researchers and health care professionals, there will also be two – 5-minute health exercises and a virtual health fair with over 30 local and national community health organizations.

“This unique online program will answer a lot of key questions about the clinical research process, how clinical trials work, and what to expect as a study participant,” said Joan Chambers, Senior Director at CISCRP. “Viewers will learn about clinical trials, straight from the patients and researchers who take part in them with a facilitated conversation and be able to submit questions via a chatbox during the program. We’re extremely excited to be presenting this event with support from a diverse team of stakeholders from the Miami community.”

AWARE for All – Miami Clinical Research Webinar will be held Tuesday, December 8th, from 4-6pm EDT. Attendance is free, but please register today by clicking here. To learn more, visit awareforall.org or call 877-633-4376.

The AWARE for All – Miami supporters include Allergy & Asthma Network, American Kidney Foundation, Arianna’s Center, Bladder Cancer Advocacy Network, Clinical Pharmacology of Miami, Clinical Site Partners, LLC, Debbie’s Dream, Florida Breast Cancer Foundation, JDRF, Latino’s Salud, Lupus Research Alliance, Myovant, NAMI, National Kidney Foundation, National MS Society, Pals for Health, Peoples Science, Segal Trials, Susan G. Komen, and the AWARE Industry Consortium.

About CISCRP

The Center for Information and Study on Clinical Research Participation (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process. CISCRP provides free education and outreach to the general public and patient communities. Visit http://www.CISCRP.org for more information or to participate in CISCRP’s educational initiatives. For additional questions about AWARE for All, contact awareforall@ciscrp.org or call 877-633-4376.

Share article on social media or email:

AltruBio presented its novel PSGL-1 agonist antibody program at FOCIS and presented its phase 2a Psoriatic Arthritis study results for lead molecule, Neihulizumab at ACR.


AltruBio Inc. http://www.altrubio.com, a clinical stage biotech company, was invited to give an overview of its PSGL-1 agonist antibody program for the treatment of T cell-mediated inflammatory diseases at the “Allergy and Inflammation” session of Federation of Clinical Immunology Societies (FOCIS) annual conference on October 29, 2020. During the session, the company highlighted research data on the novel mechanism of action as well indications clinically explored with its lead molecule, Neihulizumab. PSGL-1 has been increasingly recognized as an immune checkpoint regulator of T-cells.

Shortly after FOCIS, at ACR convergence on Nov. 7, 2020, AltruBio and Dr. Stanley Cohen of Metroplex Clinical Research Center, presented Phase 2a study results of Neihulizumab for the treatment of Psoriatic Arthritis. This single-arm, open-label Phase 2a study, led by Dr. Mark Genovese of Stanford University, aimed to investigate the efficacy as well as safety, tolerability, and immunogenicity of its lead molecule. During the study, 40% of patients (8/20) achieved ACR20 responder status at week 12. Importantly, the results of an ad hoc analysis of patients who received all 7 doses of AbGn-168H and completed the study (Completed Set) identified 8 ACR20 responders (53.3%), 6 ACR50 responders (40%), and 2 ACR70 responders (13.3%) at Week 12, suggesting there may be clinical utility with this agent for the

treatment of Psoriatic Arthritis. AltruBio is currently evaluating its plans for further advancing its PSGL-1 program in Psoriatic Arthritis.

About Neihulizumab.

Neihulizumab is an immune checkpoint agonist antibody targeting PSGL-1/CD162 that depletes chronically activated T cells. This mechanism has been evaluated in four autoimmune and inflammatory diseases and has demonstrated clinical proof of concept and safety in more than 160 patients with psoriasis, psoriatic arthritis, and biologics-refractory ulcerative colitis. This study drug is currently in Phase 1b trials for the treatment of sr-aGvHD. Phase 1 trial for the treatment of front-line acute GvHD in lieu of steroid is also initiated.

About Psoriatic Arthritis.

Psoriatic arthritis (PsA), a chronic inflammatory arthritis of unknown aetiology, involves axial and peripheral joints, nails and entheses, and is usually accompanied by psoriatic skin lesions. In the United States, an estimated 4.5 million adults suffer from psoriasis, and 1 million have PsA. The pathogenesis of PsA is thought to be mediated by inflammatory elements including T cells and the cytokine pathways they activate. The goal of treatment is to reduce joint pain and swelling, preserve joint function, slow or prevent joint damage and control psoriasis on the skin. While currently available medications including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics, particularly inhibitors of the pro-inflammatory cytokine as well as an oral phosphodiesterase 4 inhibitor Apremilast have provided therapeutic advancement, the overall response rate and maximal effectiveness of these medications have not been fully satisfactory and are associated with safety concerns of immune suppression after long term administration.

About T cell Mediated Inflammatory Diseases.

Excessive activation of T-cells can release several inflammatory mediators which cause tissue damage and, in some instances, may even trigger systemic metabolomic shift with consequences of neurological abnormality. Certain key inflammatory diseases among the worldwide population include aGvHD, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, ulcerative colitis and Crohn’s disease. Currently these diseases are routinely treated with small molecule drugs, such as steroids, methotrexate and cyclosporine, and many biologics including inhibitors of inflammatory cytokines, T-cell activation modulators, and T-cell direct targeting agents, which require life-long treatment and are associated with adverse side effects triggered by the immunosuppressive-nature of these compounds.

About AltruBio Inc. (http://www.altrubio.com)

AltruBio is a privately held biotechnology company headquartered in the San Francisco Bay Area that is focused on developing novel antibody therapeutics for the treatment of immunological diseases with high unmet medical needs. Based on unique insights into immune tolerance and epitope dominance sciences, AltruBio’s pipeline includes two clinical stage product candidates: (i) Neihulizumab (AbGn-168H) an immune checkpoint agonist antibody targeting PSGL-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and (ii) AbGn-107, an antibody-drug conjugate (ADC) employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. AbGn-107 has demonstrated encouraging results in chemo-refractory gastric, pancreatic, colorectal and biliary cancers.

Note on Forward-Looking Statements

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expects, believes, intends, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, and risks related to the Company’s ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

Share article on social media or email: